Literature DB >> 31346815

Mesalamine (5-ASA) for the prevention of recurrent diverticulitis (Review).

M Carabotti1, B Annibale2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31346815     DOI： 10.1007/s10151-019-02037-3

Source DB:  PubMed          Journal:  Tech Coloproctol        ISSN： 1123-6337            Impact factor:   3.781


× No keyword cloud information.
  13 in total

1.  American Gastroenterological Association Institute Guideline on the Management of Acute Diverticulitis.

Authors:  Neil Stollman; Walter Smalley; Ikuo Hirano
Journal:  Gastroenterology       Date:  2015-10-08       Impact factor: 22.682

2.  Italian consensus conference for colonic diverticulosis and diverticular disease.

Authors:  Rosario Cuomo; Giovanni Barbara; Fabio Pace; Vito Annese; Gabrio Bassotti; Gian Andrea Binda; Tino Casetti; Antonio Colecchia; Davide Festi; Roberto Fiocca; Andrea Laghi; Giovanni Maconi; Riccardo Nascimbeni; Carmelo Scarpignato; Vincenzo Villanacci; Bruno Annibale
Journal:  United European Gastroenterol J       Date:  2014-10       Impact factor: 4.623

3.  Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon--a placebo-controlled study.

Authors:  W Kruis; E Meier; M Schumacher; O Mickisch; R Greinwald; R Mueller
Journal:  Aliment Pharmacol Ther       Date:  2013-02-17       Impact factor: 8.171

4.  Effect of mesalazine on recurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease: a meta-analysis with trial sequential analysis of randomized controlled trials.

Authors:  R M A Khan; B Ali; S Hajibandeh; S Hajibandeh
Journal:  Colorectal Dis       Date:  2018-06       Impact factor: 3.788

5.  Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease--a double-blind, randomised, placebo-controlled study.

Authors:  A Tursi; G Brandimarte; W Elisei; M Picchio; G Forti; G Pianese; S Rodino; T D'Amico; N Sacca; P Portincasa; E Capezzuto; R Lattanzio; A Spadaccini; S Fiorella; F Polimeni; N Polimeni; V Stoppino; G Stoppino; G M Giorgetti; F Aiello; S Danese
Journal:  Aliment Pharmacol Ther       Date:  2013-08-19       Impact factor: 8.171

Review 6.  Diverticular disease: guidelines of the german society for gastroenterology, digestive and metabolic diseases and the german society for general and visceral surgery.

Authors:  Wolfgang Kruis; Christoph-Thomas Germer; Ludger Leifeld
Journal:  Digestion       Date:  2014-11-19       Impact factor: 3.216

7.  Increased risk for irritable bowel syndrome after acute diverticulitis.

Authors:  Erica Cohen; Garth Fuller; Roger Bolus; Rusha Modi; Michelle Vu; Kamyar Shahedi; Rena Shah; Mary Atia; Nicole Kurzbard; Victoria Sheen; Nikhil Agarwal; Marc Kaneshiro; Linnette Yen; Paul Hodgkins; M Haim Erder; Brennan Spiegel
Journal:  Clin Gastroenterol Hepatol       Date:  2013-03-21       Impact factor: 11.382

8.  Gut microbiota, metabolome and immune signatures in patients with uncomplicated diverticular disease.

Authors:  Giovanni Barbara; Eleonora Scaioli; Maria Raffaella Barbaro; Elena Biagi; Luca Laghi; Cesare Cremon; Giovanni Marasco; Antonio Colecchia; Gianfranco Picone; Nunzio Salfi; Francesco Capozzi; Patrizia Brigidi; Davide Festi
Journal:  Gut       Date:  2016-09-12       Impact factor: 23.059

Review 9.  Mesalamine (5-ASA) for the prevention of recurrent diverticulitis.

Authors:  Flloyd Carter; Majd Alsayb; John K Marshall; Yuhong Yuan
Journal:  Cochrane Database Syst Rev       Date:  2017-10-03

10.  Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.

Authors:  W Kruis; V Kardalinos; T Eisenbach; M Lukas; T Vich; I Bunganic; J Pokrotnieks; J Derova; J Kondrackiene; R Safadi; D Tuculanu; Z Tulassay; J Banai; A Curtin; A E Dorofeyev; S F Zakko; N Ferreira; S Björck; M M Diez Alonso; J Mäkelä; N J Talley; K Dilger; R Greinwald; R Mohrbacher; R Spiller
Journal:  Aliment Pharmacol Ther       Date:  2017-05-23       Impact factor: 8.171
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.